Cancer immunotherapies targeting the PD-1 signaling pathway

Journal of Biomedical Science

Junzo Hamanishi¹  Tasuku Honjo²  Kenji Chamoto²  Yoshiko Iwai³ 

[1] Department of Gynecology and Obstetrics, Graduate School of Medicine, Kyoto University;Department of Immunology and Genomic Medicine, Graduate School of Medicine, Kyoto University;Department of Molecular Biology, School of Medicine, University of Occupational and Environmental Health Japan;

关键词: PD-1;    PD-L1;    Cancer immunotherapy;    Immune checkpoint;   

DOI  :  10.1186/s12929-017-0329-9

来源: DOAJ

【 摘 要 】

Abstract Immunotherapy has recently emerged as the fourth pillar of cancer treatment, joining surgery, radiation, and chemotherapy. While early immunotherapies focused on accelerating T-cell activity, current immune-checkpoint inhibitors take the brakes off the anti-tumor immune responses. Successful clinical trials with PD-1 monoclonal antibodies and other immune-checkpoint inhibitors have opened new avenues in cancer immunology. However, the failure of a large subset of cancer patients to respond to these new immunotherapies has led to intensified research on combination therapies and predictive biomarkers. Here we summarize the development of PD-1-blockade immunotherapy and current issues in its clinical use.

【 授权许可】

Unknown